Cardiovascular Metabolomics
Early Detection of Cardiovascular Disease and Better Treatments
Elucidate Cardiovascular Disease Mechanisms Through Metabolomics and Lipidomics
The Global Discovery Panel provides a high-fidelity and reproducible analysis of the current state of a biological sample to help identify biomarkers and reveal changes in key biological pathways. Our unmatched chemical library can identify different classes of metabolites and pathways. Moreover, as complex lipids play an important role in the development of CVD, accurate identification and quantification provided by the Complex Lipids Targeted Panel are essential for biomarker discovery and other biological insights. Global metabolomics and lipidomics offer the opportunity to profile thousands of biochemicals in an unbiased fashion to enable the discovery of novel disease mechanisms and biomarkers.
Discover Novel Biomarkers for Early Diagnosis and Pharmacological Intervention
Understanding the underlying biology of CVD is important in identifying biomarkers that will enable disease prevention, detection, and optimal treatment efficacy. Metabolon’s reference library contains 5,400+ metabolites from serum, tissue, and cells. Our Complex Lipids Targeted Panel, which can identify up to 1100 lipid species, is the only available platform providing both complete and quantitative lipidomic analysis. Metabolomic and lipidomic profiling represent a unique and powerful platform to provide insights into the molecular processes influencing CVDs. With more than 20 years of experience and continuous innovation, Metabolon has created the industry’s most advanced system for measuring and understanding the metabolome. Metabolon’s technology can drive critical insights into the mechanisms of CVD.
See how Metabolon can advance your path to preclinical and clinical insights
Metabolomics Panels for Cardiovascular Disease
Amino Acids Targeted Panel
Beta-Hydroxybutyrate Single Analyte Assay
β-Hydroxybutyrate (BHB, 3-hydroxybutyrate) is an endogenous ketone body that accumulates during periods of fasting, calorie restriction and prolonged exercise. It is created via a multi-step process involving the break-down of fatty acids into acetyl CoA, conversion to acetoacetate and reduction to β-hydroxybutyrate in the liver. BHB is the primary ketone found in the blood and is necessary for brain function especially when glucose is unavailable. It also provides neuroprotective benefits, such as relieving oxidative stress and inhibition of apoptotic pathway in cells.
C4 Single Analyte Assay
Central Carbons Targeted Panel
Free Fatty Acids Targeted Panel
Salivary Glucose Single Analyte Assay
Impaired Glucose Tolerance Targeted Panel
Impaired Glucose Tolerance can be assessed with a single fasted blood draw by measuring a panel of selected metabolites comprised of two small organic acids (α-hydroxybutyric acid (AHB) and 4-methyl-2-oxopentanoic acid (4MOP)), 2 lipids (oleic acid and linoleoyl glycerophosphocholine (LGPC)), a ketone body (β-hydroxybutyric acid (BHBA)), an amino acid (serine), a vitamin (pantothenic acid (vitamin B5)), and glucose.
Insulin Resistance Targeted Panel
A panel of biomarkers comprised of a small organic acid (α-hydroxybutyric acid (AHB)), 2 lipids (oleic acid and linoleoylglycero-phosphocholine (LGPC)) and insulin identifies insulin resistance with a single fasting blood sample and may have value as an early indicator of risk for the development of prediabetes and type-2 diabetes.
Metal Analysis Targeted Panel
“Metabolomics is clearly linked to genotype and, more interestingly, to phenotype. It allows a unique view of the relationships among genes, gene expression, environments, lifestyles, microbiomes, treatments, and pathologies.”1
Metabolon in Action
Biomarker Discovery in Insulin Resistance
GWAS and Metabolomics Profiling to Predict Antihypertensive Drug Responses
This study leveraged the power of genomics and metabolomics to study a complex multigenetic disease and provide further insight into possible treatment options for hypertension.
Canine Mitral Valve Disease
The Metabolon Global Discovery Panel identified changes in metabolic pathways and biomarkers with potential clinical utility in canine heart disease.
Biomarkers for the Early Stages of Heart Failure
This study provides a comprehensive metabolite analysis of a rodent model of hypertension, offering insights into the changes in cardiac energy metabolism early in hypertension development. The early detection of metabolic abnormalities could serve as biomarkers for hypertension-induced left ventricular hypertrophy.
Interested in Further Studies?
Why Metabolon?
Once you see the full value of metabolomics, the only remaining question is who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare. Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.
Only Metabolon has all four core metabolomics capabilities
Coverage
Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities
Comparability
Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time
Competency
Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations
Capacity
Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand
Partner with Metabolon to access:
A library of 5,400+ known metabolites, 2,000 in human plasma, all referenced in the context of biochemical pathways
- That’s 5x the metabolites of the closest competitor
Unparalleled depth and breadth of experience analyzing and interpreting metabolomic data to find meaningful results
- 10,000+ projects with hundreds of clients
- 2,000+ publications covering 500 diseases, including numerous peer-reviewed journals such as Cell, Nature and Science
- Nearly 40 PhDs in data science, molecular biology, and biochemistry
Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.
Related Cardiovascular Disease Metabolomics Resources
Contact Us
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709
References
1. International Foundation for Functional Gastrointestinal Disorders. Facts about IBS. Available at http://www.aboutibs.org/what-is-ibs/facts-about-ibs-2.html. Accessed 08-02-2022.
2. National Institute of Health. Digestive Diseases Statistics for the United States. Available at https://www.niddk.nih.gov/health-information/health-statistics/digestive-diseases. Accessed 08-02-2022.
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660